UK Markets closed

Novo Nordisk A/S (0QIU.L)

YHD - YHD Delayed price. Currency in USD
Add to watchlist
114,191,998,976.00+19.80 (+0.00%)
At close: 05:07PM EST
Full screen
Previous closeN/A
YTD returnN/A
Expense ratio (net)N/A
CategoryN/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability rating
Net assetsN/A
Beta (5Y monthly)N/A
YieldN/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • Globe Newswire

    Novo Nordisk announces settlement of securities lawsuit in Denmark

    Bagsværd, Denmark, 14 January 2022 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs. The lawsuit was filed by a number of shareholders and alleged that Novo Nordisk had made misleading statements and did not make appropriate disclosures regarding its sales of insulin products

  • Yahoo Finance Video

    Omicron-specific vaccines are ‘already priced into COVID stocks’: Jefferies Managing Director

    Jefferies Managing Director Michael Yee joins Yahoo Finance Live’s Julie Hyman and Brian Sozzi to discuss the biotech sector, outlook for M&A activity, and the outlook for COVID-19 stocks.

  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 10 January 2022 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme